PRINCETON, N.J. --(BUSINESS WIRE)--May 18, 2022-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will present at the following healthcare conferences: H.C.
-- Multi-Center Retrospective Study was Presented at the 2022 American Urological Association Annual Meeting in New Orleans -- NEW ORLEANS --(BUSINESS WIRE)--May 16, 2022-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to creating novel solutions that treat urothelial and specialty
New data on in-office nephrostomy tube administration of JELMYTO® (mitomycin) for pyelocalyceal solution, the only non-surgical, kidney-sparing treatment for adults with low-grade upper tract urothelial cancer Results from the Phase 2b OPTIMA II trial of UGN-102 and impact of treatment in
Jelmyto® net product revenue increased 81% over Q1 2021 to $13.6 million Enrollment of UGN-102 Phase 3 single-arm, ENVISION pivotal trial is ongoing; completion of enrollment expected by end of 2022 Initiated novel, multi-arm Phase 1 clinical trial of UGN-301 in high-grade non-muscle invasive
Conference Call and Webcast Scheduled for Tuesday, May 10, 2022 at 10:00 AM ET PRINCETON, N.J. --(BUSINESS WIRE)--May 3, 2022-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today
--Multi-arm Phase 1 study will evaluate the safety, tolerability and establish the recommended Phase 2 dose of monotherapy and combination therapy to treat recurrent non-muscle invasive bladder cancer (NMIBC) --Study design utilizes Master Protocol to accelerate evaluation of combination therapies
Jelmyto® net product revenue increased 42% over Q3 2021 with $16.2 million in Q4 2021; full-year net product revenue of $48.0 million in line with guidance Announced up to $100 million senior secured term loan facility with funds managed by Pharmakon Advisors , expected to support operations to
-- Initial Draw of $75 Million Available within 10 Business Days following Closing; Second Draw of $25 Million Available through the End of 2022 -- -- Reporting of Fourth Quarter and Full-Year Financial Results Rescheduled to March 21, 2022 -- PRINCETON, N.J. --(BUSINESS WIRE)--Mar.
PRINCETON, N.J. --(BUSINESS WIRE)--Mar. 4, 2022-- UroGen Pharma Ltd. (Nasdaq: URGN) a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units (“RSUs”) to 12 new
Conference Call and Webcast Scheduled for Thursday, March 10, 2022 , at 10:00 AM ET PRINCETON, N.J. --(BUSINESS WIRE)--Mar. 4, 2022-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers,
